NATR

Business Context and Reporting Period

Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2002
Business Overview: The Company manufactures and distributes nutritional supplements through a direct sales network of independent Distributors and Managers. Operations are segmented geographically into the United States, Latin America, Asia Pacific, and Other markets.

Key Financial Metrics

Amounts in thousands, except per share data.

Margins (Six Months 2002):
- Gross Margin (Sales less COGS): 82.2%
- Operating Margin: 3.7%
- Net Profit Margin: 1.4%

Material Changes vs. Prior Period

• Revenue Decline: Sales revenue decreased 4.7% for the quarter and 5.9% for the six months compared to the prior year. This was driven primarily by a 10% decline in international operations.
• Profitability Compression: Net income dropped 35.7% for the quarter and 75.6% for the six months year-over-year. Operating income fell 42.9% (quarter) and 57.1% (six months).
• Expense Increases: Selling, General, and Administrative (SG&A) expenses increased as a percentage of sales (from 29.8% to 34.4% for the six months) due to lower sales volume and higher spending on sales conventions and travel.
• Unusual Item: The Company recorded a $3.0 million impairment loss on its investment in Cetalon Corporation during the six months ended June 30, 2002, significantly impacting other income/expense.
• Segment Performance:
  • United States: Sales declined slightly (1-2%) due to increased competition.
  • Latin America: Sales dropped 12-16% due to Brazilian import restrictions and currency devaluation in Venezuela.
  • Asia Pacific: Sales fell 11-19% due to declines in the Synergy operation and increased competition in Korea.
  • Other: Sales increased 11-16%, driven by growth in the Russian Federation.

Guidance, Outlook, and Risks

• Outlook: Management expects cost of goods sold and volume incentives to remain relatively constant as a percentage of sales for the remainder of 2002. SG&A expenses are expected to return to prior-year percentage levels as sales stabilize.
• Liquidity: Cash and cash equivalents decreased $4.4 million during the period, primarily due to a $6.0 million stock buyback program. Management believes internal funds are sufficient for working capital but noted that a prolonged economic downturn could necessitate external funding.
• Product Liability Risk: The Company faces increased regulatory scrutiny regarding products containing ephedrine alkaloids and kava. It has been unable to obtain specific insurance for these products. Premiums for general product liability coverage increased 35% with reduced coverage limits. The Company is exploring captive insurance plans.
• Foreign Exchange Risk: Approximately 42% of revenue and expenses are realized outside the U.S. A strengthening U.S. dollar negatively impacts reported results. The Company does not use derivative instruments for hedging.

Investor Verification Checklist

• Investment Impairment: Verify the details and recoverability of the $3.0 million impairment charge related to the Cetalon Corporation investment.
• Product Liability Exposure: Assess the potential financial impact of the inability to insure products containing ephedrine and kava, and the adequacy of current general liability coverage.
• International Currency Impact: Monitor exchange rate fluctuations in Brazil and Venezuela, which significantly impacted Latin American sales.
• Stock Buyback Program: Confirm the remaining balance of the authorized buyback program (251,000 shares remaining as of July 29, 2002) and its impact on future cash flow.
• Competitive Landscape: Evaluate the sustainability of the sales decline in the U.S. and Asia Pacific markets due to increased competition.